Prognostic significance of tumour variables (n=167)
| Prognostic factor | n | % |
p value (log rank) | Hazard ratio |
| Age (years) | ||||
| <Median | 82 | 49.1% | 1.00 | |
| ⩾Median | 85 | 50.9% | 0.76 | 0.94 (0.62–1.42) |
| Sex | ||||
| Female | 50 | 29.9% | 1.00 | |
| Male | 117 | 70.1% | 0.15 | 1.41 (0.88–2.25) |
| Histology | ||||
| Squamous | 103 | 61.7% | 1.00 | |
| Adenocarcinoma | 50 | 29.9% | 0.93 | 1.01 (0.64–1.60) |
| Large cell | 14 | 8.9% | 1.17 (0.53–2.57) | |
| Grade | ||||
| Well/moderate differentiated | 80 | 47.9% | 1.00 | |
| Poorly differentiated | 87 | 52.1% | 0.18 | 1.33 (0.88–2.02) |
| T | ||||
| 1 | 33 | 19.8% | 1.00 | |
| 2 | 118 | 70.7% | 0.25 | 1.15 (0.67–1.97) |
| 3 | 16 | 9.6% | 1.90 (0.87–4.16) | |
| N | ||||
| 0 | 88 | 52.7% | 1.00 | |
| 1 | 52 | 31.3% | 0.0001 | 1.55 (0.96–2.52) |
| 2 | 27 | 16.2% | 3.14 (1.84–5.37) | |
| Stage | ||||
| I | 84 | 50.3% | 1.00 | |
| II | 47 | 28.1% | 0.0001 | 1.51 (0.91–2.50) |
| IIIa | 36 | 21.6% | 2.90 (1.75–4.81) | |
| Chalkley count | ||||
| >Median | 81 | 48.5% | 0.004 | 1.84 (1.21–2.81) |
| Upper tertile | 63 | 37.7% | 0.0002 | 2.15 (1.42–3.27) |
| MMP-2 (n=162) | ||||
| Tumour +ve | 40 | 24.7% | 0.85 | 1.04 (0.65–1.70) |
| Stroma +ve | 100 | 61.7% | 0.15 | 0.73 (0.48–1.12) |
| MMP-9 | ||||
| Tumour +ve | 87 | 52.1% | 0.001 | 2.02 (1.31–3.10) |
| Stroma +ve | 78 | 46.7% | 0.94 | 0.98 (0.65–1.50) |
| EGFR | ||||
| Cytoplasm only +ve | 37 | 22.2% | 0.84 | 0.95 (0.58–1.56) |
| Membrane +ve | 55 | 32.9% | 0.14 | 1.38 (0.90–2.14) |
| Overall +ve | 92 | 55.1% | 0.24 | 1.29 (0.84–1.97) |
| Tumour cell EGFR/MMP-9 +ve | 61 | 36.5% | 0.0001 | 2.26 (1.48–3.44) |
| HercepTest score 2+ or 3+ | 3 | 1.8% | 0.56 | 1.50 (0.37–6.10) |
Hazard ratios for Chalkley count > median and upper tertile are compared with counts ⩽median and lower/middle tertile counts respectively. Hazard ratios for MMP-2, MMP-9, EGFR, and HercepTest immunoexpression are compared with cases not expressing these markers.